Cargando…

Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis

INTRODUCTION: Drug resistance (DR) in Mycobacterium tuberculosis complex (MTBC) is mainly associated with certain lineages and varies across regions and countries. The Beijing genotype is the leading resistant lineage in Asia and western countries. M. tuberculosis (Mtb) (sub) lineages responsible fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mekonnen, Daniel, Munshea, Abaineh, Nibret, Endalkachew, Adnew, Bethlehem, Getachew, Hailu, Kebede, Amiro, Gebrewahid, Ananya, Herrera-Leon, Silvia, Aramendia, Aranzazu Amor, Benito, Agustín, Abascal, Estefanía, Jacqueline, Camille, Aseffa, Abraham, Herrera-Leon, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614653/
https://www.ncbi.nlm.nih.gov/pubmed/37908783
http://dx.doi.org/10.2147/IDR.S429001
_version_ 1785129066568876032
author Mekonnen, Daniel
Munshea, Abaineh
Nibret, Endalkachew
Adnew, Bethlehem
Getachew, Hailu
Kebede, Amiro
Gebrewahid, Ananya
Herrera-Leon, Silvia
Aramendia, Aranzazu Amor
Benito, Agustín
Abascal, Estefanía
Jacqueline, Camille
Aseffa, Abraham
Herrera-Leon, Laura
author_facet Mekonnen, Daniel
Munshea, Abaineh
Nibret, Endalkachew
Adnew, Bethlehem
Getachew, Hailu
Kebede, Amiro
Gebrewahid, Ananya
Herrera-Leon, Silvia
Aramendia, Aranzazu Amor
Benito, Agustín
Abascal, Estefanía
Jacqueline, Camille
Aseffa, Abraham
Herrera-Leon, Laura
author_sort Mekonnen, Daniel
collection PubMed
description INTRODUCTION: Drug resistance (DR) in Mycobacterium tuberculosis complex (MTBC) is mainly associated with certain lineages and varies across regions and countries. The Beijing genotype is the leading resistant lineage in Asia and western countries. M. tuberculosis (Mtb) (sub) lineages responsible for most drug resistance in Ethiopia are not well described. Hence, this study aimed to identify the leading drug resistance sub-lineages and characterize first-line anti-tuberculosis drug resistance-associated single nucleotide polymorphisms (SNPs). METHODS: A facility-based cross-sectional study was conducted in 2020–2022 among new and presumptive multidrug resistant-TB (MDR-TB) cases in Northwest Ethiopia. Whole-genome sequencing (WGS) was performed on 161 isolates using Illumina NovaSeq 6000 technology. The SNP mutations associated with drug resistance were identified using MtbSeq and TB profiler Bioinformatics softwares. RESULTS: Of the 146 Mtb isolates that were successfully genotyped, 20 (13.7%) harbored one or more resistance-associated SNPs. L4.2.2.ETH was the leading drug-resistant sub-lineage, accounting for 10/20 (50%) of the resistant Mtb. MDR-TB isolates showed extensive mutations against first-line anti-TB drugs. Ser450Leu/(tcg/tTg) for Rifampicin (RIF), Ser315Thr/(agc/aCc) for Isoniazid (INH), Met306Ile/(atg/atA(C)) for Ethambutol (EMB), and Gly69Asp for Streptomycin (STR) were the leading resistance associated mutations which accounted for 56.5%, 89.5%, 47%, and 29.4%, respectively. The presence of both clustered and non-clustered drug resistance (DR) isolates indicated that the epidemics is driven by both new DR development and acquired resistance. CONCLUSION: The high prevalence of drug-resistant TB due to geographically restricted sub-lineages (L4.2.2.ETH) indicates the ongoing local micro epidemics. The Mtb drug resistance surveillance system must be improved. Further evolutionary analysis of L4.2.2.ETH strain is highly desirable to understand evolutionary forces that leads L4.2.2.ETH in to high level DR and transmissible sub-lineage.
format Online
Article
Text
id pubmed-10614653
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-106146532023-10-31 Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis Mekonnen, Daniel Munshea, Abaineh Nibret, Endalkachew Adnew, Bethlehem Getachew, Hailu Kebede, Amiro Gebrewahid, Ananya Herrera-Leon, Silvia Aramendia, Aranzazu Amor Benito, Agustín Abascal, Estefanía Jacqueline, Camille Aseffa, Abraham Herrera-Leon, Laura Infect Drug Resist Original Research INTRODUCTION: Drug resistance (DR) in Mycobacterium tuberculosis complex (MTBC) is mainly associated with certain lineages and varies across regions and countries. The Beijing genotype is the leading resistant lineage in Asia and western countries. M. tuberculosis (Mtb) (sub) lineages responsible for most drug resistance in Ethiopia are not well described. Hence, this study aimed to identify the leading drug resistance sub-lineages and characterize first-line anti-tuberculosis drug resistance-associated single nucleotide polymorphisms (SNPs). METHODS: A facility-based cross-sectional study was conducted in 2020–2022 among new and presumptive multidrug resistant-TB (MDR-TB) cases in Northwest Ethiopia. Whole-genome sequencing (WGS) was performed on 161 isolates using Illumina NovaSeq 6000 technology. The SNP mutations associated with drug resistance were identified using MtbSeq and TB profiler Bioinformatics softwares. RESULTS: Of the 146 Mtb isolates that were successfully genotyped, 20 (13.7%) harbored one or more resistance-associated SNPs. L4.2.2.ETH was the leading drug-resistant sub-lineage, accounting for 10/20 (50%) of the resistant Mtb. MDR-TB isolates showed extensive mutations against first-line anti-TB drugs. Ser450Leu/(tcg/tTg) for Rifampicin (RIF), Ser315Thr/(agc/aCc) for Isoniazid (INH), Met306Ile/(atg/atA(C)) for Ethambutol (EMB), and Gly69Asp for Streptomycin (STR) were the leading resistance associated mutations which accounted for 56.5%, 89.5%, 47%, and 29.4%, respectively. The presence of both clustered and non-clustered drug resistance (DR) isolates indicated that the epidemics is driven by both new DR development and acquired resistance. CONCLUSION: The high prevalence of drug-resistant TB due to geographically restricted sub-lineages (L4.2.2.ETH) indicates the ongoing local micro epidemics. The Mtb drug resistance surveillance system must be improved. Further evolutionary analysis of L4.2.2.ETH strain is highly desirable to understand evolutionary forces that leads L4.2.2.ETH in to high level DR and transmissible sub-lineage. Dove 2023-10-26 /pmc/articles/PMC10614653/ /pubmed/37908783 http://dx.doi.org/10.2147/IDR.S429001 Text en © 2023 Mekonnen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Mekonnen, Daniel
Munshea, Abaineh
Nibret, Endalkachew
Adnew, Bethlehem
Getachew, Hailu
Kebede, Amiro
Gebrewahid, Ananya
Herrera-Leon, Silvia
Aramendia, Aranzazu Amor
Benito, Agustín
Abascal, Estefanía
Jacqueline, Camille
Aseffa, Abraham
Herrera-Leon, Laura
Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis
title Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis
title_full Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis
title_fullStr Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis
title_full_unstemmed Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis
title_short Mycobacterium tuberculosis Sub-Lineage 4.2.2/SIT149 as Dominant Drug-Resistant Clade in Northwest Ethiopia 2020–2022: In-silico Whole-Genome Sequence Analysis
title_sort mycobacterium tuberculosis sub-lineage 4.2.2/sit149 as dominant drug-resistant clade in northwest ethiopia 2020–2022: in-silico whole-genome sequence analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614653/
https://www.ncbi.nlm.nih.gov/pubmed/37908783
http://dx.doi.org/10.2147/IDR.S429001
work_keys_str_mv AT mekonnendaniel mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT munsheaabaineh mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT nibretendalkachew mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT adnewbethlehem mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT getachewhailu mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT kebedeamiro mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT gebrewahidananya mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT herreraleonsilvia mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT aramendiaaranzazuamor mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT benitoagustin mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT abascalestefania mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT jacquelinecamille mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT aseffaabraham mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis
AT herreraleonlaura mycobacteriumtuberculosissublineage422sit149asdominantdrugresistantcladeinnorthwestethiopia20202022insilicowholegenomesequenceanalysis